Preview

Нефрология

Расширенный поиск

РЕКУРРЕНТНЫЕ ЗАБОЛЕВАНИЯ В ПЕДИАТРИЧЕСКОЙ ПОЧЕЧНОЙ ТРАНСПЛАНТАЦИИ

https://doi.org/10.24884/1561-6274-2013-17-3-9-13

Полный текст:

Аннотация

Риск развития рекуррентного заболевания после трансплантации почки у детей относительно высокий и может привести к потере трансплантата в 7–8% случаев. Рецидив основного заболевания почек может быть связан с высоким риском потери трансплантата (фокальный и сегментарный гломерулосклероз, мембранопролиферативный гломерулонефрит, оксалоз, атипичный гемолитико-уремический синдром) или с низким риском потери трансплантата (IgA-нефропатия, СКВ, ANCA-ассоциировынный гломерулонефрит). Рецидив также может повышать отсроченный риск потери трансплантата при таких заболеваниях, как инсулин-зависимый сахарный диабет и серповидно-клеточная анемия. В связи с этим необходимо применять соответствующую стратегию, например, проводить претрансплантационное генотипирование, адекватный отбор доноров, использовать специфическую иммуносупрессию и/или биотерапию, сочетанную трансплантацию почки и печени, а также другие. Это позволит значительно расширить лист ожидания за счет существенного снижения исключения пациентов из-за высокого развития рецидива. В будущем проблема рекуррентных заболеваний после трансплантации почки может решиться благодаря альтернативным методам лечения.

Об авторах

П. Коша
Centre de référence des maladies rénales rares, Service de Pédiatrie & 2.Epicime, Hôpital Femme Mère Enfant & Université de Lyon
Франция

Pierre Cochat, MD Service de pédiatrie

59 boulevard Pinel. 69677 Bron cedex; Tel: +33 4 27856125



Ж. Харамба
Néphrologie pédiatrique, Hôpital des Enfants, CHU
Франция


А-Л. Леклерк
Centre de référence des maladies rénales rares, Service de Pédiatrie & 2.Epicime, Hôpital Femme Mère Enfant & Université de Lyon
Франция


Список литературы

1. Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24: 2097-2108

2. Dall’Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after transplantation in children. Am J Kidney Dis 1999; 34: 1048-1055

3. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87: 1232-1239

4. Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 653-659

5. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12: 619-629

6. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Tranplant 2010; 10: 1517-1523

7. Samuel JP, Bell CS, Molony DA, et al. Long-term outcome of renal transplantation patients with Henoch-Schönlein purpura. Clin J Am Soc Nephrol 2011; 6: 2034-2040

8. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth review. Pediatr Transplant 2010; 14: 314-325

9. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007; 22; 496-502

10. Van Stralen KJ, Verrina E, Belingheri M, et al. Graft loss among kidney diseases with a high risk of post-transplant disease recurrence: the size of the problem in pediatric transplantation. Nephrol Dial Transplant (accepted)

11. Baum M, Ho M, Stablein D, et al. Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatr Transplant 2002; 6: 488-492

12. Saleem MA. The phenomenon of focal segmental glomerulosclerosis post-transplantation – a one-hit wonder? Pediatr Nephrol 2012 (Epub)

13. Shankland SJ, Pollak MR. A suPAR circulating factor causes kidney disease. Nature Med 2011; 17: 926-927

14. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nature Med 2011; 17: 952-961

15. Becker-Cohen R, Bruschi M, Rinat C, et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007; 7: 256-260

16. Mahesh S, Del Rio M, Feuerstein D, et al. Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplantation 2008; 12: 682-688

17. Apeland T, Hartmann A. Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 2008; 23: 2091-2094

18. Grenda R, Jarmużek W, Piatosa B, Rubik J. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation – Case report. Pediatr Transplantation 2011; 15: e121-125

19. Hristea D, Hadaya K, Marangon N, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transplant Int 2007; 20: 102-105

20. Meyer TN, Thaiss F, Stahl RAK. Immunoadsorption with rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transplant Int 2007; 20: 1066-1071

21. Okamoto M, Koshino K, Sakai K, et al. A case of recurrent focal segmental glomerulosclerosis involving massive proteinuria (> 50 g/day) immediately after renal transplantation. Clin Transplant 2011; 25: 53-58

22. Bayrakci US, Baskin E, Sakalli H, et al. Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 2009; 13: 240-243

23. Stewart ZA, Shetty R, Nair R, et al. Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen. Transplant Proc 2011; 43: 3994-3996

24. Cochat P, Ranchin B. Is there a need for a multicenter study to determine the optimal approach to recurrent nephrotic syndrome following renal transplantation? Pediatr Transplantation 2001; 5: 394-397

25. Couloures K, Pepkowitz SH, Goldfinger D, et al. Preventing recurrence of focal segmental glomerulosclerosis following renal transplantation: a case report. Pediatr Transplant 2006; 10: 962-965

26. Gonzalez E, Ettenger R, Rianthavorn P, et al. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplantation 2011; 15: 495-501

27. Fremeaux-Bacchi V. Treatment of atypical hemolytic uremic syndrome in the era of eculizumab. Clin Kidney J 2012; 5: 4-6

28. Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008; 23: 2088-2090

29. Zimmerhackl LB, Besbas N, Jungraithmayr T, et al. Epidemiology, clinical presentation, and pathophysiology of atypical hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 113-120

30. Hirt-Minkowski P, Schaub S, Mayr M, et al. Haemolytic uremic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009; 24: 3548-3551

31. Durán CE, Blasco M, Maduell F, Campistol JM. Rescue therapy with eculizumab in a transplant recipient with atypical hemolytic-uremic syndrome. Clin Kidney J 2012; 5: 28-30

32. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488-1494

33. Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-1329

34. Al-Akash SI, Stephen Almond P, Savell Jr VH, et al. Eculizumab induces long-term remission in recurrent post-transplant HUS with C3 gene mutation. Pediatr Nephrol 2011; 26: 613-619

35. Châtelet V, Lobbedez T, Fremeaux-Bacchi V, et al. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 2010; 42: 4353-4355

36. Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012; 27:1729-1736

37. Ortiz F, Gelpi R, Koskinen P, et al. IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Tranplant 2012; 27: 2553-2558

38. Moroni G, Tandardini F, Gallalli B, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005; 45: 903-911

39. Elmedehem A, Adu D, Savage COS. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003; 18: 1001-1004


Для цитирования:


Коша П., Харамба Ж., Леклерк А. РЕКУРРЕНТНЫЕ ЗАБОЛЕВАНИЯ В ПЕДИАТРИЧЕСКОЙ ПОЧЕЧНОЙ ТРАНСПЛАНТАЦИИ. Нефрология. 2013;17(3):9-16. https://doi.org/10.24884/1561-6274-2013-17-3-9-13

For citation:


Cochat P., Harambat J., Leclerc A. RECURRENT DISEASES IN PEDIATRIC RENAL TRANSPLANTATION. Nephrology (Saint-Petersburg). 2013;17(3):9-16. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-3-9-13

Просмотров: 34


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)